Please assess the completion status of the following clinical trial:

Trial Title: RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Low or intermediate-1 risk myelodysplastic syndromes by International Prognostic Scoring System (IPSS) criteria~  * IPSS score \< 1.5~* Requiring transfusion of 2 units of red blood cells at least once a month (four weeks prior to accrual on study)~* High levels of endogenous epoetin alfa (i.e., \> 200 mU/mL)~  * Unlikely to respond to epoetin alfa, or has a documented clinical non-response to epoetin alfa (at a dose of ≥ 40,000 U weekly) or darbepoetin alfa (at a dose \> 200 mcg every other week) (i.e., \< 2 g/dL increase in hemoglobin and no decrease in transfusion requirements after at least 4 weeks of treatment)~* No chronic myelomonocytic leukemia~PATIENT CHARACTERISTICS:~* ECOG Performance Status of 0-2~* Liver enzymes (AST and ALT) and total bilirubin ≤ 2 times upper limit of normal~* Serum creatinine ≤ 2 times upper limits of normal~* No clinically significant anemia due to iron, B12, or folate deficiencies; autoimmune or hereditary hemolysis; or gastrointestinal bleeding~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other serious or poorly controlled medical condition that could be exacerbated by or complicate compliance with study therapy~PRIOR CONCURRENT THERAPY:~* At least 4 weeks since prior treatment (including growth factors)~* No chronic use (\> 2 weeks) of physiologic doses of a corticosteroid agent (dose equivalent to \> 10 mg/day of prednisone) within 28 days of the first day of study drug~* No concurrent use of another investigational agent~* No concurrent therapy with any cytotoxic drugs, steroids, or growth factors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RAD001 (everolimus) (Type: EXPERIMENTAL): RAD001 (everolimus) at 10mg/day with Bone marrow aspirate/biopsy and other laboratory biomarker analysis

Based on this trial design, predict the completion outcome and termination type (if applicable).